XASE · Healthcare · Medical Devices
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.
NYSE American accepted Picard’s compliance plan, removing near-term delisting risk, but the underlying print was ugly: **$3M** revenue beat estimates, yet EPS missed by **$1.55** on a **-546.6%** margin. This remains a deeply unprofitable, subscale medical device story.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-19 | Q2 2026 | -1.50 | -1.33 | +11.33% | $3.0M | ❌ Miss | +3.34% | +197.87% | — |
| 2026-05-15 | Q1 2026 | — | -0.10 | — | $1.1M | — | +7.06% | -5.63% | +8.00% |
| 2026-03-25 |
| Q4 2025 |
| — |
| -0.06 |
| — |
| $1.0M |
| — |
| +2.02% |
| +2.94% |
| -17.06% |
| 2025-11-14 | Q3 2025 | — | -0.19 | — | $1.2M | — | — | — | — |
Showing last 4 quarters.